At the 2023 Uromigos Live & Unplugged event, Benjamin Garmezy, MD, Sarah Cannon Research Institute at Tennessee Oncology, discussed the latest RCC data that was presented at the event, and gives his thoughts on what the best treatment strategies may be for patients as well as the potential of IO-only strategies.
Uromigos Live 2023: Dr. Benjamin Garmezy on New RCC Data
By Benjamin Garmezy, MD - Last Updated: November 8, 2023Post Tags:Uromigos Live 2023-Renal Cell Carcinoma
Related Posts
Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini.
The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.
The panel discusses data related to RLTs in prostate cancer, including a recap of the VISION trial and the PSMAfore trial.
The panel breaks down the details of the PROpel, TALAPRO-2, and MAGNITUDE trials along with relevant rPFS and HR data.
The panel discussed the latest updates in NMIBC, including relevant data pertaining to pembro, atezo, and more.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.